Clinical Trials
10 trialsNCT02727803 2026-05-22
Personalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT01885689 2025-11-14
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03096782 2023-10-11
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00852709 2018-02-15
POE07-01
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT00617929 2017-12-28
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01101880 2017-10-19
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
University of Washington
Phase 2 Completed
NCT01169012 2017-08-22
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT00708721 2017-06-01
Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
University of Utah
Phase 1/2 Terminated
NCT00299156 2015-11-03
Oral Clofarabine Study in Patients With Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00293410 2010-05-06
Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed